Huons Co. Ltd (243070) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Huons Co. Ltd (243070) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩10.92 Billion ≈ $7.40 Million USD) by net assets (₩395.25 Billion ≈ $267.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Huons Co. Ltd to measure how much of total assets are equity-financed.
Huons Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Huons Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 243070 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Huons Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Huons Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hua Na Hydropower JSC
VN:HNA
|
0.043x |
|
Urbana Corporation
TO:URB-A
|
-0.006x |
|
Acrow Ltd
AU:ACF
|
0.085x |
|
Enad Global 7 AB
ST:EG7
|
0.015x |
|
City Retail Developments Tbk PT
JK:NIRO
|
-0.006x |
|
Jiangsu Zhongshe Group Co Ltd
SHE:002883
|
0.010x |
|
SillaJen Inc
KQ:215600
|
-0.040x |
|
Vuzix Corp Cmn Stk
NASDAQ:VUZI
|
-0.163x |
Annual Cash Flow Conversion Efficiency for Huons Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Huons Co. Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 243070 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩345.97 Billion ≈ $234.46 Million |
₩52.56 Billion ≈ $35.62 Million |
0.152x | -3.74% |
| 2023-12-31 | ₩330.41 Billion ≈ $223.92 Million |
₩52.14 Billion ≈ $35.34 Million |
0.158x | +39.22% |
| 2022-12-31 | ₩282.46 Billion ≈ $191.42 Million |
₩32.02 Billion ≈ $21.70 Million |
0.113x | -45.74% |
| 2021-12-31 | ₩266.09 Billion ≈ $180.33 Million |
₩55.59 Billion ≈ $37.67 Million |
0.209x | +7.28% |
| 2020-12-31 | ₩238.80 Billion ≈ $161.83 Million |
₩46.51 Billion ≈ $31.52 Million |
0.195x | -10.06% |
| 2019-12-31 | ₩194.52 Billion ≈ $131.82 Million |
₩42.12 Billion ≈ $28.54 Million |
0.217x | +69.29% |
| 2018-12-31 | ₩163.27 Billion ≈ $110.64 Million |
₩20.88 Billion ≈ $14.15 Million |
0.128x | -48.05% |
| 2017-12-31 | ₩122.69 Billion ≈ $83.15 Million |
₩30.21 Billion ≈ $20.47 Million |
0.246x | -46.72% |
| 2016-12-31 | ₩93.88 Billion ≈ $63.62 Million |
₩43.38 Billion ≈ $29.40 Million |
0.462x | -- |
About Huons Co. Ltd
Huons Co., Ltd. provides medical solutions for human health in Korea and internationally. The company offers oral solid form drugs, including circulatory system, metabolic, antipyretic, analgesic, anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, anti-coagulant, antiviral, central nervous system, antibiotic, well-being, urogenital system, and other ch… Read more